Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure

Inclusion Criteria: * Previous myocardial infarction at least 3 months ago, open infarct vessel or bypass * Left ventricular ejection fraction (LVEF) ≤ 45% on echocardiography * Stable chronic heart failure NYHA class II to III under constant (4 weeks) evidence-based optimal medical treatment * age 18 - 80 years * written informed consent * women of childbearing age: negative pregnancy test; effective contraception for the first 8 months in the trial Exclusion Criteria: * Non-ischemic cardiomyopathy * Necessity for revascularization in other vessel than the infarct vessel at the time of study therapy * Hemodynamic relevant severe valvular disease with indication for operative / interventional revision * Heart failure with preserved ejection fraction (diastolic heart failure), LVEF \> 45% * Unstable Angina * Severe peripheral artery occlusive disease (≥ Fontaine stadium III) * Active infection (C-reactive protein \> 10 mg/dl), chronic active hepatitis; any chronic inflammatory disease, HIV infection * Neoplastic disease without documented remission in the last 5 years * Stroke ≤ 3 months * Impaired renal function (Serum creatinine \> 2,5 mg/dl) at the time of study inclusion * Relevant liver disease (GOT \> 2x upper normal limit, spontaneous INR \> 1,5). * Diseases of hematopoetic system, anemia (Hemoglobin \< 8.5 mg/dl), thrombocytopenia \< 100.000/µl) * Splenomegaly * Allergy or intolerance of clopidogrel, prasugrel, ticagrelor, heparin, bivalirudin * History of bleeding disorder * gastrointestinal bleeding ≤ 3 months * major surgery or trauma ≤ 3 months * Uncontrolled hypertension * Pregnancy, lactation period * mental retardation * previous cardiac cell therapy within last 12 months * Participation in another clinical trial ≤ 30 days